Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Amicus Therapeutics (FOLD) Operating Margin (2016 - 2025)

Amicus Therapeutics' Operating Margin history spans 16 years, with the latest figure at 8.61% for Q4 2025.

  • For the quarter ending Q4 2025, Operating Margin fell 206.0% year-over-year to 8.61%, compared with a TTM value of 5.17% through Dec 2025, up 46.0%, and an annual FY2025 reading of 5.17%, up 46.0% over the prior year.
  • Operating Margin for Q4 2025 was 8.61% at Amicus Therapeutics, down from 20.27% in the prior quarter.
  • The five-year high for Operating Margin was 20.27% in Q3 2025, with the low at 95.71% in Q1 2022.
  • Average Operating Margin over 5 years is 29.28%, with a median of 22.53% recorded in 2023.
  • Year-over-year, Operating Margin crashed -2492bps in 2022 and then soared 5512bps in 2023.
  • Tracing FOLD's Operating Margin over 5 years: stood at 87.82% in 2021, then skyrocketed by 45bps to 48.05% in 2022, then surged by 93bps to 3.21% in 2023, then surged by 433bps to 10.67% in 2024, then dropped by -19bps to 8.61% in 2025.
  • Per Business Quant, the three most recent readings for FOLD's Operating Margin are 8.61% (Q4 2025), 20.27% (Q3 2025), and 6.12% (Q2 2025).